BRPI0509257A - polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo - Google Patents

polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo

Info

Publication number
BRPI0509257A
BRPI0509257A BRPI0509257-4A BRPI0509257A BRPI0509257A BR PI0509257 A BRPI0509257 A BR PI0509257A BR PI0509257 A BRPI0509257 A BR PI0509257A BR PI0509257 A BRPI0509257 A BR PI0509257A
Authority
BR
Brazil
Prior art keywords
polymorph
mammal
composition
bazedoxifene acetate
treating
Prior art date
Application number
BRPI0509257-4A
Other languages
English (en)
Inventor
Kadum A Ali
Pietro Allegrini
Aldo Belli
Roberto Brescello
Vincenzo Cannata
Malama K Chibwe
Livius Cotarca
Shridhar G Gangolli
Carl E Longfellow
Giorgio Soriato
Massimo Verzini
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0509257A publication Critical patent/BRPI0509257A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

POLIMORFO CRISTALINO DE ACETATO DE BAZEDOXIFENO, COMPOSIçãO, PROCESSO PARA PREPARAR UM POLIMORFO E PARA AUMENTAR A PROPORçãO DE ACETATO DE BAZEDOXIFENO FORMA BEM UMA COMPOSIçãO, MéTODOS DE TRATAR UM MAMìFERO, CáNCER DE MAMA E UMA MULHER EM PóS-MENOPAUSA PARA UM OU MAIS DISTúRBIOS VASOMOTORES, DE ABAIXAR COLESTEROL E DE INIBIR PERDA óSSEA EM UM MAMìFERO E USO DE UM POLIMORFO A presente invenção é dirigida a um polimorfo cristalino de acetato de bazedoxifeno, composições contendo o mesmo, preparações deste, e usos deste.
BRPI0509257-4A 2004-04-07 2005-04-06 polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo BRPI0509257A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56058404P 2004-04-07 2004-04-07
PCT/US2005/011423 WO2005100314A1 (en) 2004-04-07 2005-04-06 Crystalline polymorph of bazedoxifene acetate

Publications (1)

Publication Number Publication Date
BRPI0509257A true BRPI0509257A (pt) 2007-09-11

Family

ID=34965585

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509257-4A BRPI0509257A (pt) 2004-04-07 2005-04-06 polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo

Country Status (20)

Country Link
US (1) US7683052B2 (pt)
EP (1) EP1732889A1 (pt)
JP (2) JP2007532548A (pt)
KR (1) KR20070004815A (pt)
CN (1) CN1938271A (pt)
AR (1) AR048683A1 (pt)
AU (1) AU2005233114A1 (pt)
BR (1) BRPI0509257A (pt)
CA (1) CA2561296A1 (pt)
EC (1) ECSP066910A (pt)
GT (1) GT200500080A (pt)
IL (1) IL178101A0 (pt)
NO (1) NO20065046L (pt)
PA (1) PA8629201A1 (pt)
PE (1) PE20060173A1 (pt)
RU (1) RU2006132352A (pt)
TW (1) TW200536845A (pt)
UA (1) UA86055C2 (pt)
WO (1) WO2005100314A1 (pt)
ZA (1) ZA200608361B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070188A1 (es) * 2005-06-29 2007-03-16 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
PE20090100A1 (es) * 2007-03-30 2009-02-26 Wyeth Corp Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas
CZ302358B6 (cs) * 2007-07-25 2011-03-30 Zentiva, A. S. Nové soli bazedoxifenu
CN101977897A (zh) * 2008-02-11 2011-02-16 惠氏有限责任公司 制备乙酸巴多昔芬的多晶型a的方法
WO2009102778A1 (en) * 2008-02-11 2009-08-20 Wyeth Amorphous polymorph of bazedoxifene acetate
ITMI20091109A1 (it) * 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
AR078785A1 (es) 2009-10-27 2011-11-30 Wyeth Llc Formulaciones de bazedoxifeno con antioxidantes
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
WO2012007453A1 (en) 2010-07-14 2012-01-19 Sandoz Ag Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol
EP2616463A4 (en) 2010-09-14 2014-01-08 Reddys Lab Ltd Dr PREPARATION OF CRYSTALLINE BAZEDOXIFES AND THEIR SALTS
EP2471770A1 (en) 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
CN103864664A (zh) * 2012-12-18 2014-06-18 江苏柯菲平医药有限公司 巴多昔芬乙酸盐新晶型及其制备方法
US9751835B2 (en) 2013-05-15 2017-09-05 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
CN103864665B (zh) * 2014-03-04 2016-03-02 苏州特瑞药业有限公司 醋酸巴多昔芬的制备方法
CN104030963A (zh) * 2014-06-30 2014-09-10 四川大学 一种巴多昔芬醋酸盐晶型a的制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
DE69707189T2 (de) 1996-04-19 2002-06-20 American Home Products Corp., Madison Östrogene Verbindungen
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
NZ503793A (en) * 1997-10-15 2002-10-25 Wyeth Corp Novel aryloxy-alkyl-dialkylamines and processes for preparing these compounds
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
IL165395A0 (en) 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
PE20060676A1 (es) 2004-04-07 2006-07-24 Wyeth Corp Polimorfo cristalino de acetato de bazedoxifeno

Also Published As

Publication number Publication date
NO20065046L (no) 2006-11-06
GT200500080A (es) 2005-10-31
US20050250762A1 (en) 2005-11-10
JP2007532548A (ja) 2007-11-15
PE20060173A1 (es) 2006-04-12
JP2009007361A (ja) 2009-01-15
CA2561296A1 (en) 2005-10-27
TW200536845A (en) 2005-11-16
EP1732889A1 (en) 2006-12-20
US7683052B2 (en) 2010-03-23
AR048683A1 (es) 2006-05-17
ZA200608361B (en) 2010-03-31
PA8629201A1 (es) 2005-11-25
RU2006132352A (ru) 2008-05-20
WO2005100314A1 (en) 2005-10-27
IL178101A0 (en) 2006-12-31
ECSP066910A (es) 2006-12-20
KR20070004815A (ko) 2007-01-09
UA86055C2 (ru) 2009-03-25
AU2005233114A1 (en) 2005-10-27
CN1938271A (zh) 2007-03-28

Similar Documents

Publication Publication Date Title
BRPI0509257A (pt) polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
WO2006037024A3 (en) Salts of decitabine
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
ECSP066730A (es) Compuestos y procedimientos para uso
PH12013502369A1 (en) Diazacarbazoles and methods of use
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
MX2010001535A (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa.
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2008052005A3 (en) Compounds and methods for treating estrogen receptor-related diseases
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
EA201400245A1 (ru) Ингибиторы dyrk1 и их применение
WO2006034154A3 (en) Salts of 5-azacytidine
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
EP2224919A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS AND TUMOR-RELATED DISEASES
MX2010003495A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas.
BRPI0509191A (pt) polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
WO2010054024A3 (en) 1, 2 -thiazol yl derivatives as cannabinoid receptor ligands
MX2011012479A (es) Moduladores de los receptores 5-ht y metodos de uso de los mismos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.